The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy

References

• Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine. 2014;42(12):698–702. doi:10.1016/j.mpmed.2014.09.007
   Google Scholar
• Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377–390. doi:10.1038/s41581-020-0278-5
   PubMed Web of Science ®Google Scholar
• Kim TN, Park MS, Yang SJ, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care. 2010;33(7):1497–1499. doi:10.2337/dc09-2310
   PubMed Web of Science ®Google Scholar
• Izzo A, Massimino E, Riccardi G, et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients. 2021;13(1):183. doi:10.3390/nu13010183
   PubMed Web of Science ®Google Scholar
• Liccini A, Malmstrom TK. Frailty and sarcopenia as predictors of adverse health outcomes in persons with diabetes mellitus. J Am Med Dir Assoc. 2016;17(9):846–851. doi:10.1016/j.jamda.2016.07.007
   PubMed Web of Science ®Google Scholar
• Kawada T. Mortality risk of sarcopenia in older subjects. J Am Med Dir Assoc. 2021;22(9):1883. doi:10.1016/j.jamda.2021.04.011
   PubMed Web of Science ®Google Scholar
• Xu J, Wan CS, Ktoris K, et al. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology. 2022;68(4):361–376. doi:10.1159/000517099
   PubMed Web of Science ®Google Scholar
• Takahashi F, Hashimoto Y, Kaji A, et al. Sarcopenia is associated with a risk of mortality in people with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2021;12:783363. doi:10.3389/fendo.2021.783363
   PubMed Web of Science ®Google Scholar
• Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for sarcopenia. J Am Med Dir Assoc. 2014;15(2):95–101. doi:10.1016/j.jamda.2013.11.025
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–2646. doi:10.1016/S0140-6736(19)31138-9
   PubMed Web of Science ®Google Scholar
• Tsekoura M, Kastrinis A, Katsoulaki M, et al. Sarcopenia and its impact on quality of life. Adv Exp Med Biol. 2017;987:213–218.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601. doi:10.1093/ageing/afz046
   PubMed Web of Science ®Google Scholar
• Wu X, Li X, Xu M, et al. Sarcopenia prevalence and associated factors among older Chinese population: findings from the China Health and Retirement Longitudinal Study. PLoS One. 2021;16(3):e0247617. doi:10.1371/journal.pone.0247617
   PubMed Web of Science ®Google Scholar
• Ethgen O, Beaudart C, Buckinx F, et al. The Future prevalence of sarcopenia in Europe: a claim for public health action. Calcif Tissue Int. 2017;100(3):229–234. doi:10.1007/s00223-016-0220-9
   PubMed Web of Science ®Google Scholar
• Wen CY, Lien AS, Jiang YD. Sarcopenia in elderly diabetes. J Diabetes Investig. 2022;13(6):944–946. doi:10.1111/jdi.13752
   PubMed Web of Science ®Google Scholar
• Huang S, Xiang C, Song Y. Identification of the shared gene signatures and pathways between sarcopenia and type 2 diabetes mellitus. PLoS One. 2022;17(3):e0265221. doi:10.1371/journal.pone.0265221
   PubMed Web of Science ®Google Scholar
• Mesinovic J, Zengin A, De Courten B, et al. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019;12:1057–1072. doi:10.2147/DMSO.S186600
   PubMed Web of Science ®Google Scholar
• Lin JA, Hou JD, Wu SY. Effect of sarcopenia on mortality in type 2 diabetes: a long-term follow-up propensity score-matched diabetes cohort study. J Clin Med. 2022;11(15):4424. doi:10.3390/jcm11154424
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Khoshbakht T, Hussen BM, et al. Emerging role of non-coding RNAs in senescence. Front Cell Dev Biol. 2022;10:869011. doi:10.3389/fcell.2022.869011
   PubMed Web of Science ®Google Scholar
• Nair KS. Aging muscle. Am J Clin Nutr. 2005;81(5):953–963. doi:10.1093/ajcn/81.5.953
   PubMed Web of Science ®Google Scholar
• Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care. 2004;7(4):405–410. doi:10.1097/01.mco.0000134362.76653.b2
   PubMed Web of Science ®Google Scholar
• Mccormick R, Vasilaki A. Age-related changes in skeletal muscle: changes to life-style as a therapy. Biogerontology. 2018;19(6):519–536. doi:10.1007/s10522-018-9775-3
   PubMed Web of Science ®Google Scholar
• Son JW, Lee SS, Kim SR, et al. Low muscle mass and risk of type 2 diabetes in middle-aged and older adults: findings from the KoGES. Diabetologia. 2017;60(5):865–872. doi:10.1007/s00125-016-4196-9
   PubMed Web of Science ®Google Scholar
• Wu H, Liu M, Chi VTQ, et al. Handgrip strength is inversely associated with metabolic syndrome and its separate components in middle aged and older adults: a large-scale population-based study. Metabolism. 2019;93:61–67. doi:10.1016/j.metabol.2019.01.011
   PubMed Web of Science ®Google Scholar
• Mitchell WK, Williams J, Atherton P, et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012;3:260. doi:10.3389/fphys.2012.00260
   PubMed Web of Science ®Google Scholar
• Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-ray absorptiometry body composition reference values from NHANES. PLoS One. 2009;4(9):e7038. doi:10.1371/journal.pone.0007038
   PubMed Web of Science ®Google Scholar
• Zamboni M, Gattazzo S, Rossi AP. Myosteatosis: a relevant, yet poorly explored element of sarcopenia. Eur Geriatr Med. 2019;10(1):5–6. doi:10.1007/s41999-018-0134-3
   PubMed Web of Science ®Google Scholar
• Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes. 2006;55(6):1813–1818. doi:10.2337/db05-1183
   PubMed Web of Science ®Google Scholar
• Par A, Hegyi JP, Vancsa S, et al. Sarcopenia - 2021: pathophysiology, diagnosis, therapy. Orv Hetil. 2021;162(1):3–12. doi:10.1556/650.2021.32015
   PubMed Web of Science ®Google Scholar
• Walsh K. Adipokines, myokines and cardiovascular disease. Circ J. 2009;73(1):13–18. doi:10.1253/circj.CJ-08-0961
   PubMed Web of Science ®Google Scholar
• Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care. 2012;15(1):12–22. doi:10.1097/MCO.0b013e32834dd297
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Mcmillan DC, Horgan PG, et al. Systemic inflammation predicts all-cause mortality: a Glasgow inflammation outcome study. PLoS One. 2015;10(3):e0116206. doi:10.1371/journal.pone.0116206
   PubMed Web of Science ®Google Scholar
• Papadopoulou SK. Sarcopenia: a contemporary health problem among older adult populations. Nutrients. 2020;12(5):1293. doi:10.3390/nu12051293
   PubMed Web of Science ®Google Scholar
• Sinha-Hikim I, Cornford M, Gaytan H, et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. J Clin Endocrinol Metab. 2006;91(8):3024–3033. doi:10.1210/jc.2006-0357
   PubMed Web of Science ®Google Scholar
• Jang HC. Sarcopenia, frailty, and diabetes in older adults. Diabetes Metab J. 2016;40(3):182–189. doi:10.4093/dmj.2016.40.3.182
   PubMed Web of Science ®Google Scholar
• Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol a Biol Sci Med Sci. 2006;61(10):1059–1064. doi:10.1093/gerona/61.10.1059
   PubMed Web of Science ®Google Scholar
• Meier NF, Lee DC. Physical activity and sarcopenia in older adults. Aging Clin Exp Res. 2020;32(9):1675–1687. doi:10.1007/s40520-019-01371-8
   PubMed Web of Science ®Google Scholar
• Norman AW, Bouillon R. Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood). 2010;235(9):1034–1045. doi:10.1258/ebm.2010.010014
   PubMed Web of Science ®Google Scholar
• Dang M, Shore-Lorenti C, Mcmillan LB, et al. Associations of serum 25-hydroxyvitamin D with physical performance and bone health in overweight and obese older adults. Int J Environ Res Public Health. 2019;16(3):509. doi:10.3390/ijerph16030509
   PubMed Web of Science ®Google Scholar
• Mirhosseini N, Vatanparast H, Mazidi M, et al. Vitamin D supplementation, glycemic control, and insulin resistance in prediabetics: a meta-analysis. J Endocr Soc. 2018;2(7):687–709. doi:10.1210/js.2017-00472
   PubMed Web of Science ®Google Scholar
• Lucato P, Solmi M, Maggi S, et al. Low vitamin D levels increase the risk of type 2 diabetes in older adults: a systematic review and meta-analysis. Maturitas. 2017;100:8–15. doi:10.1016/j.maturitas.2017.02.016
   PubMed Web of Science ®Google Scholar
• Hirani V, Cumming RG, Naganathan V, et al. Longitudinal associations between vitamin d metabolites and sarcopenia in older Australian men: the concord health and aging in men project. J Gerontol a Biol Sci Med Sci. 2017;73(1):131–138. doi:10.1093/gerona/glx086
   PubMed Web of Science ®Google Scholar
• Uchitomi R, Oyabu M, Kamei Y. Vitamin D and sarcopenia: potential of vitamin D supplementation in sarcopenia prevention and treatment. Nutrients. 2020;12(10):3189. doi:10.3390/nu12103189
   PubMed Web of Science ®Google Scholar
• Remelli F, Vitali A, Zurlo A, et al. Vitamin D deficiency and sarcopenia in older persons. Nutrients. 2019;11(12):2861. doi:10.3390/nu11122861
   PubMed Web of Science ®Google Scholar
• Kalyani RR, Metter EJ, Egan J, et al. Hyperglycemia predicts persistently lower muscle strength with aging. Diabetes Care. 2015;38(1):82–90. doi:10.2337/dc14-1166
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta (GA): US Department of Health and Human Services; 2014.
   Google Scholar
• Maddatu J, Anderson-baucum E, Evans-Molina C. Smoking and the risk of type 2 diabetes. Transl Res. 2017;184:101–107. doi:10.1016/j.trsl.2017.02.004
   PubMed Web of Science ®Google Scholar
• Larsson L, Orlander J. Skeletal muscle morphology, metabolism and function in smokers and non-smokers. A study on smoking-discordant monozygous twins. Acta Physiol Scand. 1984;120(3):343–352. doi:10.1111/j.1748-1716.1984.tb07394.x
   PubMedGoogle Scholar
• Wust RC, Morse CI, De Haan A, et al. Skeletal muscle properties and fatigue resistance in relation to smoking history. Eur J Appl Physiol. 2008;104(1):103–110. doi:10.1007/s00421-008-0792-9
   PubMed Web of Science ®Google Scholar
• Degens H, Veerkamp JH. Changes in oxidative capacity and fatigue resistance in skeletal muscle. Int J Biochem. 1994;26(7):871–878. doi:10.1016/0020-711X(94)90079-5
   PubMedGoogle Scholar
• Orlander J, Kiessling KH, Larsson L. Skeletal muscle metabolism, morphology and function in sedentary smokers and nonsmokers. Acta Physiol Scand. 1979;107(1):39–46. doi:10.1111/j.1748-1716.1979.tb06440.x
   PubMedGoogle Scholar
• Degens H, Gayan-Ramirez G, Van Hees HW. Smoking-induced skeletal muscle dysfunction: from evidence to mechanisms. Am J Respir Crit Care Med. 2015;191(6):620–625. doi:10.1164/rccm.201410-1830PP
   PubMed Web of Science ®Google Scholar
• Yaribeygi H, Farrokhi FR, Butler AE, et al. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol. 2019;234(6):8152–8161. doi:10.1002/jcp.27603
   PubMed Web of Science ®Google Scholar
• Argyropoulou D, Geladas ND, Nomikos T, et al. Exercise and nutrition strategies for combating sarcopenia and type 2 diabetes mellitus in older adults. J Funct Morphol Kinesiol. 2022;7(2). doi:10.3390/jfmk7020048
   PubMedGoogle Scholar
• Giha HA, Alamin OAO, Sater MS. Diabetic sarcopenia: metabolic and molecular appraisal. Acta Diabetol. 2022;59(8):989–1000. doi:10.1007/s00592-022-01883-2
   PubMed Web of Science ®Google Scholar
• Russell ST, Rajani S, Dhadda RS, et al. Mechanism of induction of muscle protein loss by hyperglycaemia. Exp Cell Res. 2009;315(1):16–25. doi:10.1016/j.yexcr.2008.10.002
   PubMed Web of Science ®Google Scholar
• Purnamasari D, Tetrasiwi EN, Kartiko GJ, et al. Sarcopenia and chronic complications of type 2 diabetes mellitus. Rev Diabet Stud. 2022;18(3):157–165. doi:10.1900/RDS.2022.18.157
   PubMedGoogle Scholar
• Goossens GH, Blaak EE, Theunissen R, et al. Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol. 2012;50(3):142–149. doi:10.1016/j.molimm.2012.01.005
   PubMed Web of Science ®Google Scholar
• Mcbride MJ, Foley KP, D’souza DM, et al. The NLRP3 inflammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice. Am J Physiol Endocrinol Metab. 2017;313(2):E222–E232. doi:10.1152/ajpendo.00060.2017
   PubMed Web of Science ®Google Scholar
• Hirata Y, Nomura K, Senga Y, et al. Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight. 2019;4(4). doi:10.1172/jci.insight.124952
   PubMed Web of Science ®Google Scholar
• Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016;65(6):1232–1244. doi:10.1016/j.jhep.2016.07.040
   PubMed Web of Science ®Google Scholar
• Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol. 2005;37(10):1974–1984. doi:10.1016/j.biocel.2005.04.018
   PubMed Web of Science ®Google Scholar
• Yoshida T, Delafontaine P. Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells. 2020;9(9):1970. doi:10.3390/cells9091970
   PubMed Web of Science ®Google Scholar
• Lawrence JC. mTOR-dependent control of skeletal muscle protein synthesis. Int J Sport Nutr Exerc Metab. 2001;11(Suppl):S177–S185. doi:10.1123/ijsnem.11.s1.s177
   PubMedGoogle Scholar
• Bassil MS, Gougeon R. Muscle protein anabolism in type 2 diabetes. Curr Opin Clin Nutr Metab Care. 2013;16(1):83–88. doi:10.1097/MCO.0b013e32835a88ee
   PubMed Web of Science ®Google Scholar
• Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol. 2014;2(10):819–829. doi:10.1016/S2213-8587(14)70034-8
   PubMed Web of Science ®Google Scholar
• Qiu J, Thapaliya S, Runkana A, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism. Proc Natl Acad Sci U S A. 2013;110(45):18162–18167. doi:10.1073/pnas.1317049110
   PubMed Web of Science ®Google Scholar
• Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol. 2014;10(9):504–516. doi:10.1038/nrneph.2014.112
   PubMed Web of Science ®Google Scholar
• Bataille S, Chauveau P, Fouque D, et al. Myostatin and muscle atrophy during chronic kidney disease. Nephrol Dial Transplant. 2021;36(11):1986–1993. doi:10.1093/ndt/gfaa129
   PubMed Web of Science ®Google Scholar
• Du J, Wang X, Miereles C, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest. 2004;113(1):115–123. doi:10.1172/JCI18330
   PubMed Web of Science ®Google Scholar
• Baczek J, Silkiewicz M, Wojszel ZB. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020;12(8):2401. doi:10.3390/nu12082401
   PubMed Web of Science ®Google Scholar
• Buch A, Carmeli E, Boker LK, et al. Muscle function and fat content in relation to sarcopenia, obesity and frailty of old age--an overview. Exp Gerontol. 2016;76:25–32. doi:10.1016/j.exger.2016.01.008
   PubMed Web of Science ®Google Scholar
• Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107. doi:10.1038/nri2925
   PubMed Web of Science ®Google Scholar
• Perry BD, Caldow MK, Brennan-Speranza TC, et al. Muscle atrophy in patients with type 2 diabetes mellitus: roles of inflammatory pathways, physical activity and exercise. Exerc Immunol Rev. 2016;22:94–109.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li H, He M, et al. Immune system and sarcopenia: presented relationship and future perspective. Exp Gerontol. 2022;164:111823. doi:10.1016/j.exger.2022.111823
   PubMed Web of Science ®Google Scholar
• Goyal R, Faizy AF, Siddiqui SS, et al. Evaluation of TNF-alpha and IL-6 levels in obese and non-obese diabetics: pre- and postinsulin effects. N Am J Med Sci. 2012;4(4):180–184. doi:10.4103/1947-2714.94944
   PubMedGoogle Scholar
• King DE, Mainous AG, Buchanan TA, et al. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003;26(5):1535–1539. doi:10.2337/diacare.26.5.1535
   PubMed Web of Science ®Google Scholar
• Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001;9(7):414–417. doi:10.1038/oby.2001.54
   PubMedGoogle Scholar
• Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol a Biol Sci Med Sci. 2002;57(5):M326–332. doi:10.1093/gerona/57.5.M326
   PubMed Web of Science ®Google Scholar
• Rong YD, Bian AL, Hu HY, et al. Study on relationship between elderly sarcopenia and inflammatory cytokine IL-6, anti-inflammatory cytokine IL-10. BMC Geriatr. 2018;18(1):308. doi:10.1186/s12877-018-1007-9
   PubMed Web of Science ®Google Scholar
• Haddad F, Zaldivar F, Cooper DM, et al. IL-6-induced skeletal muscle atrophy. J Appl Physiol. 2005;98(3):911–917. doi:10.1152/japplphysiol.01026.2004
   PubMed Web of Science ®Google Scholar
• Park SW, Goodpaster BH, Strotmeyer ES, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007;30(6):1507–1512. doi:10.2337/dc06-2537
   PubMed Web of Science ®Google Scholar
• Ma JF, Sanchez BJ, Hall DT, et al. STAT 3 promotes IFN γ/ TNF α-induced muscle wasting in an NF -κB-dependent and IL −6-independent manner. EMBO Mol Med. 2017;9(5):622–637. doi:10.15252/emmm.201607052
   PubMed Web of Science ®Google Scholar
• Ip WKE, Hoshi N, Shouval DS, et al. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science. 2017;356(6337):513–519. doi:10.1126/science.aal3535
   PubMed Web of Science ®Google Scholar
• Omura T, Araki A. Skeletal muscle as a treatment target for older adults with diabetes mellitus: the importance of a multimodal intervention based on functional category. Geriatr Gerontol Int. 2022;22(2):110–120. doi:10.1111/ggi.14339
   PubMed Web of Science ®Google Scholar
• Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006;440(7086):944–948. doi:10.1038/nature04634
   PubMed Web of Science ®Google Scholar
• Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2015;6(3):197–207. doi:10.1002/jcsm.12043
   PubMed Web of Science ®Google Scholar
• Aragno M, Mastrocola R, Catalano MG, et al. Oxidative stress impairs skeletal muscle repair in diabetic rats. Diabetes. 2004;53(4):1082–1088. doi:10.2337/diabetes.53.4.1082
   PubMed Web of Science ®Google Scholar
• Scicchitano BM, Pelosi L, Sica G, et al. The physiopathologic role of oxidative stress in skeletal muscle. Mech Ageing Dev. 2018;170:37–44. doi:10.1016/j.mad.2017.08.009
   PubMed Web of Science ®Google Scholar
• Zhang L, Kimball SR, Jefferson LS, et al. Hydrogen peroxide impairs insulin-stimulated assembly of mTORC1. Free Radic Biol Med. 2009;46(11):1500–1509. doi:10.1016/j.freeradbiomed.2009.03.001
   PubMed Web of Science ®Google Scholar
• Short KR, Bigelow ML, Kahl J, et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A. 2005;102(15):5618–5623. doi:10.1073/pnas.0501559102
   PubMed Web of Science ®Google Scholar
• Abbatecola AM, Paolisso G, Fattoretti P, et al. Discovering pathways of sarcopenia in older adults: a role for insulin resistance on mitochondria dysfunction. J Nutr Health Aging. 2011;15(10):890–895. doi:10.1007/s12603-011-0366-0
   PubMed Web of Science ®Google Scholar
• Conley KE, Jubrias SA, Esselman PC. Oxidative capacity and ageing in human muscle. J Physiol. 2000;526(Pt 1):203–210. doi:10.1111/j.1469-7793.2000.t01-1-00203.x
   PubMed Web of Science ®Google Scholar
• Bua E, Johnson J, Herbst A, et al. Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers. Am J Hum Genet. 2006;79(3):469–480. doi:10.1086/507132
   PubMed Web of Science ®Google Scholar
• Chen H, Ma J, Liu A, et al. The association between sarcopenia and fracture in middle-aged and elderly people: a systematic review and meta-analysis of cohort studies. Injury. 2020;51(4):804–811. doi:10.1016/j.injury.2020.02.072
   PubMed Web of Science ®Google Scholar
• Hyatt HW, Powers SK. The role of calpains in skeletal muscle remodeling with exercise and inactivity-induced atrophy. Int J Sports Med. 2020;41(14):994–1008. doi:10.1055/a-1199-7662
   PubMed Web of Science ®Google Scholar
• Huang J, Zhu X. The molecular mechanisms of calpains action on skeletal muscle atrophy. Physiol Res. 2016;65(4):547–560. doi:10.33549/physiolres.933087
   PubMed Web of Science ®Google Scholar
• Suzuki A, Yabu A, Nakamura H. Advanced glycation end products in musculoskeletal system and disorders. Methods. 2022;203:179–186. doi:10.1016/j.ymeth.2020.09.012
   PubMed Web of Science ®Google Scholar
• Haus JM, Carrithers JA, Trappe SW, et al. Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol. 2007;103(6):2068–2076. doi:10.1152/japplphysiol.00670.2007
   PubMed Web of Science ®Google Scholar
• Forbes JM, Sourris KC, De Courten MP, et al. Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. Amino Acids. 2014;46(2):321–326. doi:10.1007/s00726-013-1542-9
   PubMed Web of Science ®Google Scholar
• Moon SS. Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009–2010. Endocr J. 2014;61(1):61–70. doi:10.1507/endocrj.EJ13-0244
   PubMed Web of Science ®Google Scholar
• Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. 2016;229(2):R67–81. doi:10.1530/JOE-15-0533
   PubMed Web of Science ®Google Scholar
• Waqas K, Chen J, Trajanoska K, et al. Skin autofluorescence, a noninvasive biomarker for advanced glycation end-products, is associated with sarcopenia. J Clin Endocrinol Metab. 2022;107(2):e793–e803. doi:10.1210/clinem/dgab632
   PubMed Web of Science ®Google Scholar
• Boettcher M, Machann J, Stefan N, et al. Intermuscular adipose tissue (IMAT): association with other adipose tissue compartments and insulin sensitivity. J Magn Reson Imaging. 2009;29(6):1340–1345. doi:10.1002/jmri.21754
   PubMed Web of Science ®Google Scholar
• Scott D, Shore-Lorenti C, Mcmillan LB, et al. Calf muscle density is independently associated with physical function in overweight and obese older adults. J Musculoskelet Neuronal Interact. 2018;18(1):9–17.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846. doi:10.1038/nature05482
   PubMed Web of Science ®Google Scholar
• Pellegrinelli V, Rouault C, Rodriguez-Cuenca S, et al. Human Adipocytes Induce Inflammation and Atrophy in Muscle Cells During Obesity. Diabetes. 2015;64(9):3121–3134. doi:10.2337/db14-0796
   PubMed Web of Science ®Google Scholar
• Bittel DC, Bittel AJ, Tuttle LJ, et al. Adipose tissue content, muscle performance and physical function in obese adults with type 2 diabetes mellitus and peripheral neuropathy. J Diabetes Complications. 2015;29(2):250–257. doi:10.1016/j.jdiacomp.2014.11.003
   PubMed Web of Science ®Google Scholar
• Meex RCR, Blaak EE, Van Loon LJC. Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes. Obes Rev. 2019;20(9):1205–1217. doi:10.1111/obr.12862
   PubMed Web of Science ®Google Scholar
• Jimenez-Gutierrez GE, Martínez-Gómez LE, Martínez-Armenta C, et al. Molecular mechanisms of inflammation in sarcopenia: diagnosis and therapeutic update. Cells. 2022;11(15):2359. doi:10.3390/cells11152359
   PubMed Web of Science ®Google Scholar
• Csapo R, Malis V, Sinha U, et al. Age-associated differences in triceps surae muscle composition and strength - an MRI-based cross-sectional comparison of contractile, adipose and connective tissue. BMC Musculoskelet Disord. 2014;15:209. doi:10.1186/1471-2474-15-209
   PubMed Web of Science ®Google Scholar
• Ticinesi A, Nouvenne A, Cerundolo N, et al. Gut microbiota, muscle mass and function in aging: a focus on physical frailty and sarcopenia. Nutrients. 2019;11(7):1633. doi:10.3390/nu11071633
   PubMed Web of Science ®Google Scholar
• Bouter KE, Van Raalte DH, Groen AK, et al. Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. Gastroenterology. 2017;152(7):1671–1678. doi:10.1053/j.gastro.2016.12.048
   PubMed Web of Science ®Google Scholar
• Utzschneider KM, Kratz M, Damman CJ, et al. Mechanisms linking the gut microbiome and glucose metabolism. J Clin Endocrinol Metab. 2016;101(4):1445–1454. doi:10.1210/jc.2015-4251
   PubMed Web of Science ®Google Scholar
• Allin KH, Tremaroli V, Caesar R, et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia. 2018;61(4):810–820. doi:10.1007/s00125-018-4550-1
   PubMed Web of Science ®Google Scholar
• Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. doi:10.1038/nature11450
   PubMed Web of Science ®Google Scholar
• Kootte RS, Levin E, Salojarvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26(4):611–619 e616. doi:10.1016/j.cmet.2017.09.008
   PubMed Web of Science ®Google Scholar
• Strasser B, Wolters M, Weyh C, et al. The effects of lifestyle and diet on gut microbiota composition, inflammation and muscle performance in our aging society. Nutrients. 2021;13(6):2045. doi:10.3390/nu13062045
   PubMed Web of Science ®Google Scholar
• Park S, Yuan H, Zhang T, et al. Long-term silk peptide intake promotes skeletal muscle mass, reduces inflammation, and modulates gut microbiota in middle-aged female rats. Biomed Pharmacother. 2021;137:111415. doi:10.1016/j.biopha.2021.111415
   PubMed Web of Science ®Google Scholar
• Houghton MJ, Kerimi A, Mouly V, et al. Gut microbiome catabolites as novel modulators of muscle cell glucose metabolism. FASEB J. 2019;33(2):1887–1898. doi:10.1096/fj.201801209R
   PubMed Web of Science ®Google Scholar
• Van Krimpen SJ, Jansen FAC, Ottenheim VL, et al. The effects of pro-, pre-, and synbiotics on muscle wasting, a systematic review-gut permeability as potential treatment target. Nutrients. 2021;13(4):1115. doi:10.3390/nu13041115
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang Y, Ni Y, et al. Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention. Cell Metab. 2020;31(1):77–91 e75. doi:10.1016/j.cmet.2019.11.001
   PubMed Web of Science ®Google Scholar
• Burini RC, Anderson E, Durstine JL, et al. Inflammation, physical activity, and chronic disease: an evolutionary perspective. Sports Med Health Sci. 2020;2(1):1–6. doi:10.1016/j.smhs.2020.03.004
   PubMedGoogle Scholar
• Liu HW, Chang SJ. Moderate exercise suppresses NF-kappaB Signaling and activates the SIRT1-AMPK-PGC1alpha axis to attenuate muscle loss in diabetic db/db mice. Front Physiol. 2018;9:636. doi:10.3389/fphys.2018.00636
   PubMed Web of Science ®Google Scholar
• Dent E, Morley JE, Cruz-Jentoft AJ, et al. International clinical practice guidelines for sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging. 2018;22(10):1148–1161. doi:10.1007/s12603-018-1139-9
   PubMed Web of Science ®Google Scholar
• Dhillon RJ, Hasni S. Pathogenesis and management of sarcopenia. Clin Geriatr Med. 2017;33(1):17–26. doi:10.1016/j.cger.2016.08.002
   PubMed Web of Science ®Google Scholar
• Reidy PT, Mahmassani ZS, Mckenzie AI, et al. Influence of exercise training on skeletal muscle insulin resistance in aging: spotlight on muscle ceramides. Int J Mol Sci. 2020;21(4):1514. doi:10.3390/ijms21041514
   PubMed Web of Science ®Google Scholar
• Kimura T, Okamura T, Iwai K, et al. Japanese radio calisthenics prevents the reduction of skeletal muscle mass volume in people with type 2 diabetes. BMJ Open Diabetes Res Care. 2020;8(1):e001027. doi:10.1136/bmjdrc-2019-001027
   PubMed Web of Science ®Google Scholar
• Zhao D, Shi W, Bi L, et al. Effect of short-term acute moderate-intensity resistance exercise on blood glucose in older patients with type 2 diabetes mellitus and sarcopenia. Geriatr Gerontol Int. 2022;22(8):653–659. doi:10.1111/ggi.14437
   PubMed Web of Science ®Google Scholar
• Zhang XZ, Xie WQ, Chen L, et al. Blood flow restriction training for the intervention of sarcopenia: current stage and future perspective. Front Med. 2022;9:894996. doi:10.3389/fmed.2022.894996
   Web of Science ®Google Scholar
• Shang X, Scott D, Hodge AM, et al. Dietary protein intake and risk of type 2 diabetes: results from the Melbourne Collaborative Cohort Study and a meta-analysis of prospective studies. Am J Clin Nutr. 2016;104(5):1352–1365. doi:10.3945/ajcn.116.140954
   PubMed Web of Science ®Google Scholar
• Manders RJ, Little JP, Forbes SC, et al. Insulinotropic and muscle protein synthetic effects of branched-chain amino acids: potential therapy for type 2 diabetes and sarcopenia. Nutrients. 2012;4(11):1664–1678. doi:10.3390/nu4111664
   PubMed Web of Science ®Google Scholar
• Low S, Wang J, Moh A, et al. Amino acid profile of skeletal muscle loss in type 2 diabetes: results from a 7-year longitudinal study in asians. Diabetes Res Clin Pract. 2022;186:109803. doi:10.1016/j.diabres.2022.109803
   PubMed Web of Science ®Google Scholar
• Hamarsland H, Nordengen AL, Nyvik Aas S, et al. Native whey protein with high levels of leucine results in similar post-exercise muscular anabolic responses as regular whey protein: a randomized controlled trial. J Int Soc Sports Nutr. 2017;14:43. doi:10.1186/s12970-017-0202-y
   PubMed Web of Science ®Google Scholar
• Jayanama K, Theou O, Godin J, et al. Association of fatty acid consumption with frailty and mortality among middle-aged and older adults. Nutrition. 2020;70:110610. doi:10.1016/j.nut.2019.110610
   PubMed Web of Science ®Google Scholar
• Smith GI, Atherton P, Reeds DN, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr. 2011;93(2):402–412. doi:10.3945/ajcn.110.005611
   PubMed Web of Science ®Google Scholar
• Kiecolt-glaser JK, Belury MA, Andridge R, et al. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun. 2012;26(6):988–995. doi:10.1016/j.bbi.2012.05.011
   PubMed Web of Science ®Google Scholar
• Ganapathy A, Nieves JW. Nutrition and sarcopenia-what do we know? Nutrients. 2020;12(6):1755. doi:10.3390/nu12061755
   PubMed Web of Science ®Google Scholar
• Tamura Y, Omura T, Toyoshima K, et al. Nutrition management in older adults with diabetes: a review on the importance of shifting prevention strategies from metabolic syndrome to frailty. Nutrients. 2020;12(11):3367. doi:10.3390/nu12113367
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Takahashi F, Kaji A, et al. Eating speed is associated with the presence of sarcopenia in older patients with type 2 diabetes: a cross-sectional study of the KAMOGAWA-DM cohort. Nutrients. 2022;14(4):759. doi:10.3390/nu14040759
   PubMed Web of Science ®Google Scholar
• Hamstra SI, Roy BD, Tiidus P, et al. Beyond its psychiatric use: the benefits of low dose lithium supplementation. Curr Neuropharmacol. 2022. doi:10.2174/1570159X20666220302151224
   Web of Science ®Google Scholar
• Atkinson RA, Srinivas-Shankar U, Roberts SA, et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J Gerontol A Biol Sci Med Sci. 2010;65(11):1215–1219. doi:10.1093/gerona/glq118
   PubMed Web of Science ®Google Scholar
• Papanicolaou DA, Ather SN, Zhu H, et al. A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging. 2013;17(6):533–543. doi:10.1007/s12603-013-0335-x
   PubMed Web of Science ®Google Scholar
• Neto WK, Gama EF, Rocha LY, et al. Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies. Age. 2015;37(1):9742. doi:10.1007/s11357-014-9742-0
   PubMedGoogle Scholar
• Narayanan R, Coss CC, Dalton JT. Development of selective androgen receptor modulators (SARMs). Mol Cell Endocrinol. 2018;465:134–142. doi:10.1016/j.mce.2017.06.013
   PubMed Web of Science ®Google Scholar
• Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled Phase II trial. J Cachexia Sarcopenia Muscle. 2011;2(3):153–161. doi:10.1007/s13539-011-0034-6
   PubMed Web of Science ®Google Scholar
• Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84–94. doi:10.1016/j.sxmr.2018.09.006
   PubMed Web of Science ®Google Scholar
• Wu CN, Tien KJ. The impact of antidiabetic agents on sarcopenia in type 2 diabetes: a literature review. J Diabetes Res. 2020;2020:9368583. doi:10.1155/2020/9368583
   PubMed Web of Science ®Google Scholar
• Massimino E, Izzo A, Riccardi G, et al. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms. Cells. 2021;10(8):1958. doi:10.3390/cells10081958
   PubMed Web of Science ®Google Scholar
• Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. doi:10.1210/jc.2015-3754
   PubMed Web of Science ®Google Scholar
• Cetrone M, Mele A, Tricarico D. Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. Curr Diabetes Rev. 2014;10(4):231–237. doi:10.2174/1573399810666140918121022
   PubMedGoogle Scholar
• Mele A, Calzolaro S, Cannone G, et al. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol Res Perspect. 2014;2(1):e00028. doi:10.1002/prp2.28
   PubMedGoogle Scholar
• Sanz-Canovas J, Lopez-Sampalo A, Cobos-Palacios L, et al. Management of type 2 diabetes mellitus in elderly patients with frailty and/or sarcopenia. Int J Environ Res Public Health. 2022;19(14):8677. doi:10.3390/ijerph19148677
   PubMed Web of Science ®Google Scholar
• Yokota T, Kinugawa S, Hirabayashi K, et al. Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. J Diabetes Investig. 2017;8(4):535–541. doi:10.1111/jdi.12606
   PubMed Web of Science ®Google Scholar
• Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773–2778. doi:10.2337/dc07-0717
   PubMed Web of Science ®Google Scholar
• Sencan C, Dost FS, Ates Bulut E, et al. DPP4 inhibitors as a potential therapeutic option for sarcopenia: a 6-month follow-up study in diabetic older patients. Exp Gerontol. 2022;164:111832. doi:10.1016/j.exger.2022.111832
   PubMed Web of Science ®Google Scholar
• Doucet J, Chacra A, Maheux P, et al. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011;27(4):863–869. doi:10.1185/03007995.2011.554532
   PubMed Web of Science ®Google Scholar
• Bamba R, Okamura T, Hashimoto Y, et al. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice. J Cachexia Sarcopenia Muscle. 2022;13(1):574–588. doi:10.1002/jcsm.12814
   PubMed Web of Science ®Google Scholar
• Yabe D, Shiki K, Suzaki K, et al. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open. 2021;11(4):e045844. doi:10.1136/bmjopen-2020-045844
   PubMed Web of Science ®Google Scholar
• Kumar A, Davuluri G, Welch N, et al. Oxidative stress mediates ethanol-induced skeletal muscle mitochondrial dysfunction and dysregulated protein synthesis and autophagy. Free Radic Biol Med. 2019;145:284–299. doi:10.1016/j.freeradbiomed.2019.09.031
   PubMed Web of Science ®Google Scholar
• Lee SJ, Mcpherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A. 2001;98(16):9306–9311. doi:10.1073/pnas.151270098
   PubMed Web of Science ®Google Scholar
• Dasarathy S, Mccullough AJ, Muc S, et al. Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol. 2011;54(5):915–921. doi:10.1016/j.jhep.2010.08.032
   PubMed Web of Science ®Google Scholar
• Tsai CH, Huang PJ, Lee IT, et al. Endothelin-1-mediated miR-let-7g-5p triggers interleukin-6 and TNF-α to cause myopathy and chronic adipose inflammation in elderly patients with diabetes mellitus. Aging. 2022;14(8):3633–3651. doi:10.18632/aging.204034
   PubMedGoogle Scholar